Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2021 | CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL

Paolo Ghia, MD, PhD, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy, shares the latest updates from the Phase II CAPTIVATE trial (NCT02910583) exploring the efficacy and safety of ibrutinib plus venetoclax in patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This study involves two cohorts; one in which there is fixed-duration of treatment and another which is guided by measurable residual disease (MRD) status. Dr Ghia comments on the latest findings of this trial, which show that the progression-free survival rate after one year was 95% in patients receiving fixed-duration therapy, independent of MRD levels and genetic aberrations. Although this data indicates that fixed-duration combination therapy could be effective even in the absence of drugs, it is necessary to re-evaluate those results within a longer time frame. This interview took place at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held virtually in 2021.